Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype

Masataka Takenaka; Martin Kobel; Dale W Garsed; Sian Fereday; Ahwan Pandey; Dariush Etemadmoghadam; Joy Hendley; Ayako Kawabata; Daito Noguchi; Nozomu Yanaihara; Hiroyuki Takahashi; Takako Kiyokawa; Masahiro Ikegami; Hirokuni Takano; Seiji Isonishi; Kazuhiko Ochiai; Nadia Traficante; Sreeja Gadipally; Timothy Semple; Dane Vassiliadis; Kausyalya Amarasinghe; Jason Li; Gisela Mir Arnau; Aikou Okamoto; Michael Friedlander; David DL Bowtell

Journal article

Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype

Masataka Takenaka, Martin Kobel, Dale W Garsed, Sian Fereday, Ahwan Pandey, Dariush Etemadmoghadam, Joy Hendley, Ayako Kawabata, Daito Noguchi, Nozomu Yanaihara, Hiroyuki Takahashi, Takako Kiyokawa, Masahiro Ikegami, Hirokuni Takano, Seiji Isonishi, Kazuhiko Ochiai, Nadia Traficante, Sreeja Gadipally, Timothy Semple, Dane Vassiliadis Show all

CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019

DOI: 10.1158/1078-0432.CCR-18-3691

Abstract

PURPOSE: Although ovarian clear cell carcinomas (OCCC) are commonly resistant to platinum-based chemotherapy, good clinical outcomes are observed in a subset of patients. The explanation for this is unknown but may be due to misclassification of high-grade serous ovarian cancer (HGSOC) as OCCC or mixed histology. EXPERIMENTAL DESIGN: To discover potential biomarkers of survival benefit following platinum-based chemotherapy, we ascertained a cohort of 68 Japanese and Australian patients in whom progression-free survival (PFS) and overall survival (OS) could be assessed. We performed IHC reclassification of tumors, and targeted sequencing and immunohistochemistry of known driver genes. Exome s..

View full abstract

University of Melbourne Researchers

Dale Garsed Author The Sir Peter Maccallum Department of Oncology

Julie Fereday Author The Sir Peter Maccallum Department of Oncology

Nadia Traficante Author The Sir Peter Maccallum Department of Oncology

Kaushalya Amarasinghe Author The Sir Peter Maccallum Department of Oncology

Dane Vassiliadis Author The Sir Peter Maccallum Department of Oncology

Related Projects (4)

IMPROVING OUTCOMES FOR WOMEN WITH EPITHELIAL OVARIAN CANCER

nan

THE MOLECULAR BIOLOGY OF HUMAN OVARIAN CANCER

The Fellowship would support Professor Bowtell, one of the world’s leading ovarian cancer researchers. His work focuses on clinical problems..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by NHMRC Research Fellowship

Awarded by U.S. Army Medical Research and Materiel Command

Awarded by Cancer Foundation of Western Australia

Awarded by NHMRC

Funding Acknowledgements

The AOCS gratefully acknowledges the cooperation of the participating institutions in Australia, and also acknowledges the study nurses, research assistants and all clinical and scientific collaborators including Misato Saito, Kazuya Sakurai, and Haruka Yanagisawa. The complete AOCS Group can be found at www.aocstudy.org.We would like to thank all of the women who participated in the study. This study was financially supported by the National Health and Medical Research Council of Australia (NHMRC) Program Grant APP1092856 "Improving outcomes for women with ovarian cancer" (to M. Friedlander and D.D.L. Bowtell), and the NHMRC Research Fellowship Grant APP1117044 "The molecular biology of human ovarian cancer" (to D.D.L. Bowtell). The AOCS was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, the Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania, and The Cancer Foundation of Western Australia (Multi-State Applications 191, 211, and 182) and the NHMRC (ID400413 and ID400281). The AOCS gratefully acknowledges additional support from S. Boldeman, the Agar family, Ovarian Cancer Action (UK), Ovarian Cancer Australia, and the Peter MacCallum Foundation.